Advertisement

MDXG

MiMedx Group, Inc.

Healthcare · USD

Set alert

Price alert · MDXG

All alert types
3.88 USD -0.09 -2.27%
As of Oct 30, 2026 Extended hours 3.88 0.00%
Bid
3.89 × 2
Ask
3.90 × 1
3.79 Day range 3.99
3.09 52-week range 7.96
YTD
-42.69%
1 year
-47.57%
Open
3.98
Prev close
3.97
Mkt cap
566.19M
Vol
2.12M
Avg vol
1.30M
EPS
-0.13
P/E
0.00
Div yield
0.00%
More statistics
Low
3.79
High
3.99
Forward P/E
21.65
Beta
1.73
Short ratio
11.09
Inst. own
71.52%
Dividend
0.00
Ex-div date
Earnings
Feb 25, 2026
50-d avg
7.05
200-d avg
7.43
1y target
12.20

2Y chart

Chart tools
Interval
MDXG two-year price chart3.034.816.598.3610.1Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
992.81M
Enterprise value
910.15M
Trailing P/E
31.95
Forward P/E
21.65
PEG ratio
0.00
Price / sales
2.73
Price / book
4.58
EPS (TTM)
0.21
Beta
1.73
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
8.84%
Revenue (TTM)
363.77M
Revenue growth
13.10%
Free cash flow
46.09M
Total cash
118.87M
Total debt
18.46M
Return on equity
16.61%
Shares outstanding
147.96M
Short % of float
4.02%
50-day average
7.05
200-day average
7.43

Analyst view

Consensus: none

Price target (mean) 12.20 +214.4% upside
Target (low)
12.00
Target (mean)
12.20
Target (high)
13.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy5
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Feb 25, 2026

Expected Feb 25, 2026. Consensus EPS estimate 0.075.

Earnings history

Financials — quick view

All financials
MDXG Revenue — quarterly 62.28M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
MDXG Net income — quarterly -8.68M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
MDXG EPS — quarterly -0.06
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

MDXG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2026Dec 1, 20250.09———
Oct 29, 2025Sep 1, 20250.070.15+0.08+114.29%
Jul 30, 2025Jun 1, 20250.060.10+0.04+66.67%
Apr 30, 2025Mar 1, 20250.060.060.000.00%
Feb 26, 2025Dec 1, 20240.070.070.000.00%
Oct 30, 2024Sep 1, 20240.050.07+0.02+40.00%

Upgrades / downgrades

MDXG analyst upgrades and downgrades
DateFirmActionFromTo
Jul 31, 2025Cantor FitzgeraldmainOverweightOverweight
Jul 15, 2025Cantor FitzgeraldreitOverweightOverweight
Feb 27, 2025Cantor FitzgeraldreitOverweightOverweight
Aug 1, 2024Cantor FitzgeraldreitOverweightOverweight
Aug 1, 2024Craig-HallummainBuyBuy
Jul 2, 2024Cantor Fitzgeraldinit—Overweight

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
mimedx.com

News

Your note

Sign in to keep a note on MDXG — it syncs with the Stock Master app.

Insider holders

MDXG insider holders
InsiderRelationLatest transactionDateShares held
BEHRENS M KATHLEENDirectorStock Award(Grant)Jun 17, 2025212,771
BIERMAN JAMES LDirectorStock Award(Grant)Jun 17, 2025212,771
CAPPER JOSEPH HChief Executive OfficerPurchaseMay 1, 2025529,530
HAWKINS WILLIAM A IIIDirectorStock Award(Grant)Jun 17, 2025204,018
HULSE WILLIAM FRANK IVGeneral CounselSaleMar 12, 2025440,178
KIMBERLY MAERSK-MOLLEROfficerSaleMar 16, 2025309,077

Institution ownership

MDXG institution ownership
Holder% heldSharesValueReported
Essex Woodlands Management Inc.25.56%28,195,249189.19MJun 29, 2025
Blackrock Inc.10.45%11,525,79077.34MJun 29, 2025
Trigran Investments Inc7.61%8,390,45856.30MJun 29, 2025
Vanguard Group Inc6.31%6,957,25046.68MJun 29, 2025
Paradigm Capital Management4.04%4,452,39629.88MJun 29, 2025
State Street Corporation3.14%3,465,91323.26MJun 29, 2025

Fund ownership

MDXG fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.20%3,530,54023.69MJun 29, 2025
iShares Trust-iShares Russell 2000 ETF2.54%2,802,36018.80MJul 30, 2025
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.68%1,852,12512.43MJun 29, 2025
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.08%1,190,1227.99MJul 30, 2025
iShares Trust-iShares Russell 2000 Growth ETF0.95%1,042,4797.00MAug 30, 2025
Harbor Funds II-Embark Small Cap Equity Fund0.86%947,8776.36MJul 30, 2025
Advertisement